Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ronald Chen

Radiation Oncology Kansas City, KS Medical Doctor

NPI 1265510309 CMS profile 969402

4001 Rainbow Blvd, Ms 4033, Kansas City, KS 66160

Open in the dashboard

General payments

$31,000

45 records reported · program years 2019–2025

Research payments

$8,696

Paid to them · 7 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,365,634 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Ronald Chen of Kansas City, KS is reported in the CMS Open Payments database as having received $31,000 across 45 general payments and $8,696 in research payments paid to them. Separately, studies naming them as principal investigator received $2,365,634 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Radiation Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $26 1
2025 Research $4,337 1
2024 General $3,126 6
2023 General $4,751 9
2023 Research $1,708 2
2022 General $9,813 14
2022 Research $2,651 4
2021 General $7,614 5
2020 General $3,770 7
2019 General $1,900 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ronald Chen
  • Radiation Oncology median
  • Middle half of Radiation Oncology
  • National median

In program year 2025, general payments to Ronald Chen were reported at $26. Among 3,409 Radiation Oncology profiles paid that year, the median was $172 and the middle half received between $61 and $514.

Show as a table
Year Ronald Chen Radiation Oncology median Middle half National median
2019 $1,900 $138 $48–$462 $163
2020 $3,770 $79 $26–$262 $114
2021 $7,614 $119 $37–$358 $132
2022 $9,813 $139 $43–$424 $149
2023 $4,751 $167 $57–$473 $160
2024 $3,126 $168 $56–$541 $164
2025 $26 $172 $61–$514 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Myovant Sciences Inc. $4,850 1 payment
  2. AbbVie, Inc. $4,613 8 payments
  3. Astellas Pharma Global Development $4,084 7 payments
  4. Siemens Medical Solutions USA, Inc. $2,809 12 payments
  5. Novartis Pharmaceuticals Corporation $2,538 1 payment
  6. Bayer HealthCare Pharmaceuticals Inc. $2,160 1 payment
  7. Janssen Scientific Affairs, LLC $2,150 2 payments
  8. RefleXion Medical, Inc. $1,624 2 payments
  9. Janssen Biotech, Inc. $1,440 1 payment
  10. Telix Pharmaceuticals $1,402 2 payments
  11. Other $3,332 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $18,194 22 payments
  2. Travel and Lodging $5,422 11 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,850 1 payment
  4. Honoraria $1,544 2 payments
  5. Food and Beverage $991 9 payments
Products named General payments · program years 2019–2025
  1. ORGOVYX $4,850 1 payment
  2. PADCEV $4,084 7 payments
  3. ERLEADA $3,590 3 payments
  4. Varian Ethos Treatment Planning $2,523 9 payments
  5. LUPRON DEPOT $2,363 3 payments
  6. Xofigo $2,160 1 payment
  7. REFLEXION MEDICAL RADIOTHERAPY SYSTEM $1,624 2 payments
  8. ILLUCCIX $1,402 2 payments
  9. Halcyon $1,031 3 payments
  10. CyberKnife System $1,000 1 payment
  11. Other $1,868 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Astellas Pharma Global Development $4,359 6 payments
  2. Novartis Pharmaceuticals Corporation $4,337 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

23

Median for Radiation Oncology: 65

Drug cost

$359

Median for Radiation Oncology: $978

Branded share of claims

0%

Median for Radiation Oncology: 7.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tamsulosin Hcl Generic 23 $359

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,680 Part D prescribers listed as Radiation Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$77,054

Medicare's payments for the services billed

Medicare patients

205

Average age 73

Services billed

1,061

69 women, 136 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 72%
High blood pressure 65%
Arthritis 44%
Ischemic heart disease 29%
Diabetes 21%
Atrial fibrillation 19%
Depression 18%
COPD 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

52 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Radiation Oncology in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record